Hydroxamic Astacin Inhibitors for Selective Metalloproteinase Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current inhibitors for astacin metalloproteinases, particularly procollagen C-proteinase (PCP) enzymes, meprins, ovastacin, and nematode astacins, lack selectivity and are associated with side effects, and there is a need for more effective treatments for diseases related to these enzymes.
Innovation Solution
Development of novel hydroxamic acid derivatives that selectively inhibit PCP enzymes, meprins, ovastacin, and nematode astacins, while minimizing effects on other metalloproteinases like ADAMs and MMPs, with acceptable drug-like properties.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing inhibitors for astacin metalloproteinases are used, then inhibition activity is achieved, but selectivity is poor and side effects occur
Solution Approach 1:
The patent applies local quality by designing inhibitors with specific structural features (hydroxamic acid motif at P1 position, aromatic/heteroaromatic rings at P2-P4 positions) that create localized chemical properties tailored to bind selectively to the active site of astacin metalloproteinases. This localized structural design enables the inhibitor to interact specifically with the zinc ion and conserved residues (His2, His14, His23, Glu24) in the active site, achieving high selectivity and reducing off-target side effects.
Solution Approach 2:
The patent employs parameter changes by systematically varying chemical parameters of the inhibitor molecules, including the substitution patterns on aromatic rings (positions 2, 3, 4, 5, 6), the length and type of side chains at P2-P4 positions, and the configuration of the hydroxamic acid group. These parameter modifications optimize the binding affinity and selectivity for different astacin family members while minimizing interactions with other metalloproteinases.
2Adaptability or versatility
If broad-spectrum metalloproteinase inhibitors are used, then multiple enzymes are inhibited, but specificity for target enzymes is reduced
Solution Approach 1:
The patent applies segmentation by dividing the inhibitor molecule into distinct functional segments: a P1 hydroxamic acid group that binds to the zinc ion, a P2 aromatic/heteroaromatic ring that interacts with conserved histidine residues, and P3-P4 side chains that provide specificity for different astacin family members. This segmented design allows each region to contribute to specific binding interactions, enabling the inhibitor to selectively target specific enzymes within the astacin family while maintaining overall coverage.
Solution Approach 2:
The patent uses the hydroxamic acid group as an intermediary element that mediates the interaction between the inhibitor and the zinc ion in the active site. This intermediary structure serves as a bridge to access the deep active site cleft and coordinate with the conserved histidine residues, thereby facilitating selective binding to astacin metalloproteinases while avoiding non-specific interactions with other metalloproteinase families.
3Ease of manufacture
If inhibitor structure is simplified, then manufacturing is easier, but binding affinity and selectivity may be compromised
Solution Approach 1:
The patent applies universality by designing a core hydroxamic acid derivative structure that serves multiple functions: the P1 hydroxamic acid group provides zinc ion coordination and general protease inhibition activity, while the aromatic/heteroaromatic rings at P2-P4 positions provide selective binding to different astacin family members. This universal core structure can be systematically modified at various positions to create specific inhibitors for different targets, maintaining ease of manufacture through a common synthetic pathway while achieving high binding affinity and selectivity through targeted substitutions.
Data Source
AI summary
The present invention relates to novel hydroxamic acid derivatives useful as inhibitors of astacin metalloproteinases, in particular procollagen C-proteinase (PCP) enzymes, meprins, ovastacin and/or nematode astacins; more particularly human or mammalian meprin α, meprin β, BMP-1, ovastacin and/or DPY-31 from nematodes; pharmaceutical compositions comprising such compounds; methods for treatment or prophylaxis of diseases or conditions, especially such that are related to said metalloproteinases; and compounds and pharmaceutical compositions for use in such methods